Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study

BACKGROUND: Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Søgaard, Mette, Nielsen, Peter Brønnum, Skjøth, Flemming, Kjældgaard, Jette Nordstrøm, Larsen, Torben Bjerregaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434207/
https://www.ncbi.nlm.nih.gov/pubmed/30767432
http://dx.doi.org/10.1002/cam4.1997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434207/
https://www.ncbi.nlm.nih.gov/pubmed/30767432
http://dx.doi.org/10.1002/cam4.1997

Ejemplares similares